At the completion of this activity, the participant will be able to:
1. Describe driver mutations and the importance of molecular testing in patients with non-small cell lung cancer (NSCLC)
2. Review current literature and guidelines supporting targeted therapies for MET exon 14 skipping mutations and RET rearrangements
3. Discuss medication dosing, safety, and monitoring for MET and RET targeted therapies
4. Identify alterations in ERBB2/HER2 as an evolving target for advanced NSCLC